A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
收藏DataCite Commons2025-06-25 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011169/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.
本研究旨在基于研究者放射学评估，对比AGS-16C3F与阿昔替尼（axitinib）在转移性肾细胞癌受试者中的无进展生存期（progression free survival, PFS）。
提供机构：
Vivli
创建时间：
2025-03-06
